Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Celgene gets global rights to MorphoSys' CD38 project MOR202; rights returned

Executive Summary

Celgene Corp. has licensed worldwide rights to therapeutic antibody developer MorphoSys AG’s MOR202, a fully human mAb that targets CD38 and is in Phase I/IIa trials for relapsed/refractory multiple myeloma.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register